世界の血液悪性腫瘍市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hematological Malignancies Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2763
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、血液悪性腫瘍のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（白血病、リンパ腫、骨髄腫、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・血液悪性腫瘍の市場動向
・企業の競争状況、市場シェア
・血液悪性腫瘍の種類別市場規模（白血病、リンパ腫、骨髄腫、その他）
・血液悪性腫瘍の用途別市場規模（病院、クリニック、その他）
・血液悪性腫瘍の北米市場規模2016-2027（アメリカ、カナダ）
・血液悪性腫瘍のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・血液悪性腫瘍のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・血液悪性腫瘍の中南米市場規模2016-2027（メキシコ、ブラジル）
・血液悪性腫瘍の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（AbbVie、Bristol-Myers Squibb、Celgene、Roche、GlaxoSmithKline、Johnson & Johnson、Novartis、Pfizer、Teva Pharmaceutical）
・結論

Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system.

Market Analysis and Insights: Global Hematological Malignancies Market
The global Hematological Malignancies market size is projected to reach US$ 39360 million by 2026, from US$ 29310 million in 2019, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematological Malignancies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematological Malignancies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematological Malignancies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematological Malignancies market.

Global Hematological Malignancies Scope and Market Size
Hematological Malignancies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hematological Malignancies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Leukemia
Lymphoma
Myeloma
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Bristol-Myers Squibb
Celgene
Roche
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Teva Pharmaceutical

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Malignancies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematological Malignancies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hematological Malignancies Market Perspective (2016-2027)
2.2 Hematological Malignancies Growth Trends by Regions
2.2.1 Hematological Malignancies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hematological Malignancies Historic Market Share by Regions (2016-2021)
2.2.3 Hematological Malignancies Forecasted Market Size by Regions (2022-2027)
2.3 Hematological Malignancies Industry Dynamic
2.3.1 Hematological Malignancies Market Trends
2.3.2 Hematological Malignancies Market Drivers
2.3.3 Hematological Malignancies Market Challenges
2.3.4 Hematological Malignancies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancies Players by Revenue
3.1.1 Global Top Hematological Malignancies Players by Revenue (2016-2021)
3.1.2 Global Hematological Malignancies Revenue Market Share by Players (2016-2021)
3.2 Global Hematological Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematological Malignancies Revenue
3.4 Global Hematological Malignancies Market Concentration Ratio
3.4.1 Global Hematological Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Revenue in 2020
3.5 Hematological Malignancies Key Players Head office and Area Served
3.6 Key Players Hematological Malignancies Product Solution and Service
3.7 Date of Enter into Hematological Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hematological Malignancies Breakdown Data by Type
4.1 Global Hematological Malignancies Historic Market Size by Type (2016-2021)
4.2 Global Hematological Malignancies Forecasted Market Size by Type (2022-2027)

5 Hematological Malignancies Breakdown Data by Application
5.1 Global Hematological Malignancies Historic Market Size by Application (2016-2021)
5.2 Global Hematological Malignancies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hematological Malignancies Market Size (2016-2027)
6.2 North America Hematological Malignancies Market Size by Type
6.2.1 North America Hematological Malignancies Market Size by Type (2016-2021)
6.2.2 North America Hematological Malignancies Market Size by Type (2022-2027)
6.2.3 North America Hematological Malignancies Market Size by Type (2016-2027)
6.3 North America Hematological Malignancies Market Size by Application
6.3.1 North America Hematological Malignancies Market Size by Application (2016-2021)
6.3.2 North America Hematological Malignancies Market Size by Application (2022-2027)
6.3.3 North America Hematological Malignancies Market Size by Application (2016-2027)
6.4 North America Hematological Malignancies Market Size by Country
6.4.1 North America Hematological Malignancies Market Size by Country (2016-2021)
6.4.2 North America Hematological Malignancies Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Hematological Malignancies Market Size (2016-2027)
7.2 Europe Hematological Malignancies Market Size by Type
7.2.1 Europe Hematological Malignancies Market Size by Type (2016-2021)
7.2.2 Europe Hematological Malignancies Market Size by Type (2022-2027)
7.2.3 Europe Hematological Malignancies Market Size by Type (2016-2027)
7.3 Europe Hematological Malignancies Market Size by Application
7.3.1 Europe Hematological Malignancies Market Size by Application (2016-2021)
7.3.2 Europe Hematological Malignancies Market Size by Application (2022-2027)
7.3.3 Europe Hematological Malignancies Market Size by Application (2016-2027)
7.4 Europe Hematological Malignancies Market Size by Country
7.4.1 Europe Hematological Malignancies Market Size by Country (2016-2021)
7.4.2 Europe Hematological Malignancies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hematological Malignancies Market Size (2016-2027)
8.2 Asia-Pacific Hematological Malignancies Market Size by Type
8.2.1 Asia-Pacific Hematological Malignancies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hematological Malignancies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hematological Malignancies Market Size by Type (2016-2027)
8.3 Asia-Pacific Hematological Malignancies Market Size by Application
8.3.1 Asia-Pacific Hematological Malignancies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hematological Malignancies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hematological Malignancies Market Size by Application (2016-2027)
8.4 Asia-Pacific Hematological Malignancies Market Size by Region
8.4.1 Asia-Pacific Hematological Malignancies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hematological Malignancies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hematological Malignancies Market Size (2016-2027)
9.2 Latin America Hematological Malignancies Market Size by Type
9.2.1 Latin America Hematological Malignancies Market Size by Type (2016-2021)
9.2.2 Latin America Hematological Malignancies Market Size by Type (2022-2027)
9.2.3 Latin America Hematological Malignancies Market Size by Type (2016-2027)
9.3 Latin America Hematological Malignancies Market Size by Application
9.3.1 Latin America Hematological Malignancies Market Size by Application (2016-2021)
9.3.2 Latin America Hematological Malignancies Market Size by Application (2022-2027)
9.3.3 Latin America Hematological Malignancies Market Size by Application (2016-2027)
9.4 Latin America Hematological Malignancies Market Size by Country
9.4.1 Latin America Hematological Malignancies Market Size by Country (2016-2021)
9.4.2 Latin America Hematological Malignancies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hematological Malignancies Market Size (2016-2027)
10.2 Middle East & Africa Hematological Malignancies Market Size by Type
10.2.1 Middle East & Africa Hematological Malignancies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hematological Malignancies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hematological Malignancies Market Size by Type (2016-2027)
10.3 Middle East & Africa Hematological Malignancies Market Size by Application
10.3.1 Middle East & Africa Hematological Malignancies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hematological Malignancies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hematological Malignancies Market Size by Application (2016-2027)
10.4 Middle East & Africa Hematological Malignancies Market Size by Country
10.4.1 Middle East & Africa Hematological Malignancies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hematological Malignancies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Hematological Malignancies Introduction
11.1.4 AbbVie Revenue in Hematological Malignancies Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Hematological Malignancies Introduction
11.2.4 Bristol-Myers Squibb Revenue in Hematological Malignancies Business (2016-2021)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Celgene
11.3.1 Celgene Company Details
11.3.2 Celgene Business Overview
11.3.3 Celgene Hematological Malignancies Introduction
11.3.4 Celgene Revenue in Hematological Malignancies Business (2016-2021)
11.3.5 Celgene Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Hematological Malignancies Introduction
11.4.4 Roche Revenue in Hematological Malignancies Business (2016-2021)
11.4.5 Roche Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Hematological Malignancies Introduction
11.5.4 GlaxoSmithKline Revenue in Hematological Malignancies Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Hematological Malignancies Introduction
11.6.4 Johnson & Johnson Revenue in Hematological Malignancies Business (2016-2021)
11.6.5 Johnson & Johnson Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Hematological Malignancies Introduction
11.7.4 Novartis Revenue in Hematological Malignancies Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Hematological Malignancies Introduction
11.8.4 Pfizer Revenue in Hematological Malignancies Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Details
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Hematological Malignancies Introduction
11.9.4 Teva Pharmaceutical Revenue in Hematological Malignancies Business (2016-2021)
11.9.5 Teva Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hematological Malignancies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Leukemia
Table 3. Key Players of Lymphoma
Table 4. Key Players of Myeloma
Table 5. Key Players of Others
Table 6. Global Hematological Malignancies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Hematological Malignancies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hematological Malignancies Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Hematological Malignancies Market Share by Regions (2016-2021)
Table 10. Global Hematological Malignancies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Hematological Malignancies Market Share by Regions (2022-2027)
Table 12. Hematological Malignancies Market Trends
Table 13. Hematological Malignancies Market Drivers
Table 14. Hematological Malignancies Market Challenges
Table 15. Hematological Malignancies Market Restraints
Table 16. Global Hematological Malignancies Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Hematological Malignancies Market Share by Players (2016-2021)
Table 18. Global Top Hematological Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies as of 2020)
Table 19. Ranking of Global Top Hematological Malignancies Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Hematological Malignancies Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hematological Malignancies Product Solution and Service
Table 23. Date of Enter into Hematological Malignancies Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Hematological Malignancies Revenue Market Share by Type (2016-2021)
Table 27. Global Hematological Malignancies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Hematological Malignancies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Hematological Malignancies Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Hematological Malignancies Revenue Market Share by Application (2016-2021)
Table 31. Global Hematological Malignancies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Hematological Malignancies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Hematological Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Hematological Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Hematological Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Hematological Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Hematological Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Hematological Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Hematological Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Hematological Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Hematological Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Hematological Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hematological Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hematological Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Hematological Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Hematological Malignancies Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Hematological Malignancies Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Hematological Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Hematological Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Hematological Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Hematological Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Hematological Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hematological Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hematological Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hematological Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Hematological Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Hematological Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Hematological Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 63. AbbVie Company Details
Table 64. AbbVie Business Overview
Table 65. AbbVie Hematological Malignancies Product
Table 66. AbbVie Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 67. AbbVie Recent Development
Table 68. Bristol-Myers Squibb Company Details
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb Hematological Malignancies Product
Table 71. Bristol-Myers Squibb Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 72. Bristol-Myers Squibb Recent Development
Table 73. Celgene Company Details
Table 74. Celgene Business Overview
Table 75. Celgene Hematological Malignancies Product
Table 76. Celgene Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 77. Celgene Recent Development
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Hematological Malignancies Product
Table 81. Roche Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 82. Roche Recent Development
Table 83. GlaxoSmithKline Company Details
Table 84. GlaxoSmithKline Business Overview
Table 85. GlaxoSmithKline Hematological Malignancies Product
Table 86. GlaxoSmithKline Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 87. GlaxoSmithKline Recent Development
Table 88. Johnson & Johnson Company Details
Table 89. Johnson & Johnson Business Overview
Table 90. Johnson & Johnson Hematological Malignancies Product
Table 91. Johnson & Johnson Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 92. Johnson & Johnson Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis Hematological Malignancies Product
Table 96. Novartis Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 101. Pfizer Recent Development
Table 102. Teva Pharmaceutical Company Details
Table 103. Teva Pharmaceutical Business Overview
Table 104. Teva Pharmaceutical Hematological Malignancies Product
Table 105. Teva Pharmaceutical Revenue in Hematological Malignancies Business (2016-2021) & (US$ Million)
Table 106. Teva Pharmaceutical Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Malignancies Market Share by Type: 2020 VS 2027
Figure 2. Leukemia Features
Figure 3. Lymphoma Features
Figure 4. Myeloma Features
Figure 5. Others Features
Figure 6. Global Hematological Malignancies Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Hematological Malignancies Report Years Considered
Figure 11. Global Hematological Malignancies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Hematological Malignancies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Hematological Malignancies Market Share by Regions: 2020 VS 2027
Figure 14. Global Hematological Malignancies Market Share by Regions (2022-2027)
Figure 15. Global Hematological Malignancies Market Share by Players in 2020
Figure 16. Global Top Hematological Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Hematological Malignancies Revenue in 2020
Figure 18. Global Hematological Malignancies Revenue Market Share by Type (2016-2021)
Figure 19. Global Hematological Malignancies Revenue Market Share by Type (2022-2027)
Figure 20. North America Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Hematological Malignancies Market Share by Type (2016-2027)
Figure 22. North America Hematological Malignancies Market Share by Application (2016-2027)
Figure 23. North America Hematological Malignancies Market Share by Country (2016-2027)
Figure 24. United States Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Hematological Malignancies Market Share by Type (2016-2027)
Figure 28. Europe Hematological Malignancies Market Share by Application (2016-2027)
Figure 29. Europe Hematological Malignancies Market Share by Country (2016-2027)
Figure 30. Germany Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Hematological Malignancies Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Hematological Malignancies Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Hematological Malignancies Market Share by Region (2016-2027)
Figure 40. China Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Hematological Malignancies Market Share by Type (2016-2027)
Figure 48. Latin America Hematological Malignancies Market Share by Application (2016-2027)
Figure 49. Latin America Hematological Malignancies Market Share by Country (2016-2027)
Figure 50. Mexico Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Hematological Malignancies Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Hematological Malignancies Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Hematological Malignancies Market Share by Country (2016-2027)
Figure 56. Turkey Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Hematological Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AbbVie Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 61. Celgene Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 64. Johnson & Johnson Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 66. Pfizer Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 67. Teva Pharmaceutical Revenue Growth Rate in Hematological Malignancies Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

以下、関連資料のご紹介

世界の血液悪性腫瘍市場規模・現状・予測（2021年-2027年）

Global Hematologic Malignancies Market Size, Status and Forecast 2021-2027
QYR2104Z2759 2021年4月 97Pages
QYResearch社発行の本調査資料では、血液悪性腫瘍のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（白血病、リンパ腫、多発性骨髄腫、その他）、用途別市場規模（化学療法、放射線療法、免疫療法、幹細胞移植、その他）、主要地域別市場規模（北米、ア...

世界の血液悪性腫瘍性疾患市場規模・現状・予測（2021年-2027年）

Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027
QYR2104Z2762 2021年4月 128Pages
QYResearch社発行の本調査資料では、血液悪性腫瘍性疾患のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、免疫療法、標的療法、放射線療法、幹細胞移植、その他）、用途別市場規模（白血病、リンパ腫、骨髄腫、その他）、主要地域別市場規模...

世界の血液悪性腫瘍性疾患市場 2021：企業別、地域別、種類・用途別

Global Hematological Malignancies Disease Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z06862 2021年4月 123Pages
当調査資料では、血液悪性腫瘍性疾患のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。血液悪性腫瘍性疾患の種類別市場規模（化学療法、免疫療法、標的療法、放射線療法、幹細胞移植、その他）、用途別市場規模（白血病、リンパ腫、骨髄腫、その他）、地域別市場規模（北...

世界の非血液がん市場規模・現状・予測（2021年-2027年）

Global Non-Hematological Cancers Market Size, Status and Forecast 2021-2027
QYR2104Z4164 2021年4月 97Pages
QYResearch社発行の本調査資料では、非血液がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、手術、放射線療法、その他）、用途別市場規模（病院、腫瘍治療センター、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、...

世界の非血液がん治療市場規模・現状・予測（2021年-2027年）

Global Non-Hematological Cancer Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4163 2021年4月 98Pages
QYResearch社発行の本調査資料では、非血液がん治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、手術、放射線療法、その他）、用途別市場規模（病院、腫瘍治療センター、外来手術センター、その他）、主要地域別市場規模（北米、アメリ...

世界の非血液がん治療市場規模・現状・予測（2021年-2027年）

世界の造血系疾患用治療薬・診断市場規模・現状・予測（2021年-2027年）

Global Drugs and Diagnostics for Hematological Disorders Market Size, Status and Forecast 2021-2027
QYR2104Z1997 2021年4月 92Pages
QYResearch社発行の本調査資料では、造血系疾患用治療薬・診断のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（分析装置、試薬）、用途別市場規模（学術研究所、ポイントオブケア検査、患者自己診断、バイオ医薬品産業、病院、臨床検査室）、主要地域...

世界の造血系疾患診断・治療市場規模・現状・予測（2021年-2027年）

Global Hematological Disorders Diagnostic and Therapeutic Market Size, Status and Forecast 2021-2027
QYR2104Z2761 2021年4月 99Pages
QYResearch社発行の本調査資料では、造血系疾患診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、物理）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド...

世界の造血系疾患診断・治療市場規模・現状・予測（2021年-2027年）

世界の血液がん市場規模・現状・予測（2021年-2027年）

Global Hematological Cancers Market Size, Status and Forecast 2021-2027
QYR2104Z2760 2021年4月 129Pages
QYResearch社発行の本調査資料では、血液がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬理療法、幹細胞移植、手術・放射線療法、貧血治療、血栓症治療、ニュートペニア治療、対症療法）、用途別市場規模（免疫、白血病幹細胞病態生理、腎臓病...

世界の血液悪性腫瘍性疾患市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Hematological Malignancies Disease Market The global Hematological Malignancies Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high …
世界の血液悪性腫瘍性疾患市場 2021：企業別、地域別、種類・用途別 The Hematological Malignancies Disease market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
世界の血液悪性腫瘍市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Hematologic Malignancies Market The global Hematologic Malignancies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
世界の非血液がん市場規模・現状・予測（2021年-2027年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
世界の非血液がん治療市場規模・現状・予測（2021年-2027年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…